Not sure its allowed, but it would be worth it just to see a price that keeps me out of the red
Printable View
Well we know you are not thick W69, the market however, has been duped many times on PE announcements and yep, I say totally misunderstood the situation here again
I suppose we should have expected that management should have least known when the finalization process needed to be made.
By the same token I don't think that we could expect that they insistently rattle Novitas into providing updates about their decision making process.
Management provide as much info as they can to ensure that they get a favourable outcome. Thats all you can expect them to do, so I am not that phased that they did not get the dates correct. Its a bit of a mute point anyway because it does not appear that Novitas is obliged to meet that deadline.
I'm assuming that the 15% rise today is predicated on the fact that a late finalisation improves the odds of a positive outcome. If PEB is removed from the non reimbursement list, I doubt it will drive the SP much more than around 20c although it could go 50c on a speculative short term spike. The main issue is where I agree with Psychic and that is there is still no endorsement from the AUA nor the NCCN. Until that happens the SP will settle below $1.00 for quite some time based on the expected growth rate with or without reimbursement.
In conclusion, the Cxbladder line of tests all suffer from the foundational problem of insufficient validation of their test in potentially confounding clinical circumstances including non-urothelial carcinoma malignancies and inflammatory conditions of the urinary tract. Cxbladder also demonstrates several population biases, including early papers with a strong bias towards male patients of European ancestry. The majority of Cxbladder papers avoid disclosing the PPV and number of false positives of their tests. Cxbladder tests generally have low PPVs (down to 15-16% as seen in Konety, et al 2019) and high numbers of false positives (also in Konety, et al 2019, there were 464 false positive results as compared to 86 true positive results).49 These values are significant in that false test results, particularly false positives, can lead to patient anxiety and distress among other procedural issues related to follow up for an inaccurate result. Most of the primary literature regarding Cxbladder test development and performance is funded, if not directly written by, the test’s parent company, Pacific Edge Diagnostics. This conflict of interest must be taken into account when reviewing these papers. Finally, and most importantly, due to the insufficient representation of confounding factors in the validation populations, the Cxbladder tests have not been adequately vetted in the context of the Medicare population. Given all of these findings, the Cxbladder line of tests are considered not medically reasonable and necessary for Medicare patients.
https://www.cms.gov/medicare-coverag...d=39365&ver=80
It appears it’s what SHs have been waiting for, but click the link and DYOR.
well that's that then, terrible news for shareholders. Just as revenue started to really pick up